TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24361227

Group type: EXPERIMENTAL
Intervention: Paclitaxel and gemcitabine (PG) chemotherapy
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: SLC28A3 SNP (rs7867504, C/T)
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: SLC29A1 GA haplotype
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: RRM1 SNP (rs9937) and haplotypes ATAA and ATGA
Number of subjects: 324
Study: 22120252

Group type: EXPERIMENTAL
Intervention: Enteral nimodipine
Number of subjects: 171

Group type: COMPARATOR
Intervention: Intravenous nimodipine
Number of subjects: 171
Study: 19130963

Group type: EXPERIMENTAL
Intervention: Harmonic scalpel (HS)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Clamp-and-tie technique
Number of subjects: 37
Study: 17230307

Group type: EXPERIMENTAL
Intervention: Nerve decompression without transposition
Number of subjects: 66

Group type: COMPARATOR
Intervention: Subcutaneous anterior transposition of the nerve
Number of subjects: 66
Study: 15241758

Group type: EXPERIMENTAL
Intervention: Robotic therapy for the paretic upper limb (sensorimotor active‐assistive exercise or progressive‐resistive training)
Number of subjects: 42
Study: 11782827

Group type: EXPERIMENTAL
Intervention: Creatine monohydrate (20g/d)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo maltodextrin powder
Number of subjects: 16
Study: 9696215

Group type: EXPERIMENTAL
Intervention: Bromocriptine treatment
Number of subjects: 64

Group type: COMPARATOR
Intervention: No bromocriptine treatment (Control)
Number of subjects: 64
Study: 7808246

Group type: EXPERIMENTAL
Intervention: L-carnitine supplementation (6 g.d-1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Heparin administration (2000 units 15 min prior to exercise)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 0
Study: 2532868

Group type: EXPERIMENTAL
Intervention: Loratadine 10 mg
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 938185

Group type: EXPERIMENTAL
Intervention: Psychotherapy alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Electroconvulsive therapy (ECT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Drug alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Drug plus psychotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Milieu therapy
Number of subjects: 0
Study: 29782228

Group type: EXPERIMENTAL
Intervention: Web-based self-management intervention
Number of subjects: 0
Study: 28582809

Group type: EXPERIMENTAL
Intervention: Galacto-oligosaccharides (GOS) 1.0 g twice a day for 12 weeks
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control (vehicle)
Number of subjects: 100
Study: 24599830

Group type: EXPERIMENTAL
Intervention: Calcium carbonate
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Sevelamer
Number of subjects: 113

Group type: COMPARATOR
Intervention: Phosphorus-restricted diet
Number of subjects: 113
Study: 23388530

Group type: EXPERIMENTAL
Intervention: Inderal (10 mg a day for 10‐20 minutes before meals) and Rozaliak cream (2 times a day)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group received a full comprehensive treatment complex including short courses of antibiotics, systemic metronidazole, antihistamines, desensitizing agents, traditional external therapy (Rosamet, 0.75% metronidazole cream)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Inderal and Rozaliak cream
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group treatment
Number of subjects: 25
Study: 21612650

Group type: EXPERIMENTAL
Intervention: Repositioning (RPS)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Sitting forward lean (SFL)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Sitting knee extension (SKE)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Bent knee fall out (BKFO)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Leg lowering (LL)
Number of subjects: 40
Study: 19388883

Group type: EXPERIMENTAL
Intervention: Arm-crank exercise training (twice weekly for 12 weeks)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Non-exercise control group
Number of subjects: 57
Study: 16978278

Group type: EXPERIMENTAL
Intervention: Introital ultrasonography (IUS) with a convex probe
Number of subjects: 383
Study: 15549277

Group type: EXPERIMENTAL
Intervention: Caffeine (400 mg)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Carisoprodol (700 mg)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Placebo (lactose)
Number of subjects: 94
Study: 11544435

Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids (3.4 g/day)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 9333880

Group type: EXPERIMENTAL
Intervention: Former workers exposed to fluoride
Number of subjects: 169

Group type: COMPARATOR
Intervention: Control group (29 men not exposed to fluoride)
Number of subjects: 169
Study: 8316658

Group type: EXPERIMENTAL
Intervention: Low dose radiotherapy (LD‐RT) of 5 x 2 Gy (arm A: 32 patients)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: High dose radiotherapy (HD‐RT) of either 10 x 2 Gy (arm B1; 8 patients) or 5 x 3.5 Gy (arm B2; 20 patients)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Additional diphosphonates
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: No medication
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 60
Study: 3593901

Group type: EXPERIMENTAL
Intervention: Felodipine 5 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Felodipine 15 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Felodipine 40 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Felodipine 1 mg (IV)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Felodipine 3 mg (IV)
Number of subjects: 0
Study: 30647815

Group type: EXPERIMENTAL
Intervention: Obese group (BMI > 30 kg/m2)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Overweight group (25 kg/m2 < BMI < 30 kg/m2)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group (BMI < 25 kg/m2)
Number of subjects: 61
Study: 27371769

Group type: EXPERIMENTAL
Intervention: Intensive Lifestyle Intervention (ILS)
Number of subjects: 886

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 886

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 886
Study: 24828850

Group type: EXPERIMENTAL
Intervention: PVB group (20 mL of 0.5% bupivacaine in the T9‐10 paravertebral space)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: PVB group
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (only general anesthesia)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study: 22397953

Group type: EXPERIMENTAL
Intervention: tocilizumab (4 or 8 mg/kg)
Number of subjects: 299
Study: 21062179

Group type: EXPERIMENTAL
Intervention: Revolution IQ with Quick Release (QR)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Traditional (Trad)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: ION 4D (ION)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Traditional with hardware altered (TradAlt)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Revolution IQ with Quick Release hardware altered (QRAlt)
Number of subjects: 25
Study: 19067812

Group type: EXPERIMENTAL
Intervention: Mapping and ablation of AFL using the CARTO 3D mapping system (Biosense Webster, Diamond Bar, CA, USA)
Number of subjects: 220

Group type: COMPARATOR
Intervention: No further ablation
Number of subjects: 220
Study: 16685051

Group type: EXPERIMENTAL
Intervention: Zinc sulfate 10 mg tablets twice a day during hospitalization
Number of subjects: 299

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: Zinc supplementation
Number of subjects: 299
Study: 15324519

Group type: EXPERIMENTAL
Intervention: Olopatadine 0.1% (Opatanol; Patanol)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Ketotifen 0.025% (Zaditen; Zaditor)
Number of subjects: 100
Study: 11502700

Group type: EXPERIMENTAL
Intervention: Lifestick resuscitation
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional resuscitation
Number of subjects: 50
Study: 9301400

Group type: EXPERIMENTAL
Intervention: Magnesium sulphate 60 mg kg‐1
Number of subjects: 30

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 30
Study: 8419695

Group type: EXPERIMENTAL
Intervention: Indomethacin alone
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Indomethacin combined with thymopentin
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no immunomodulatory therapy)
Number of subjects: 60
Study: 2943311

Group type: EXPERIMENTAL
Intervention: Spironolactone (200 mg daily)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 30497077

Group type: EXPERIMENTAL
Intervention: Classical Turkish music therapy
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group (no music therapy)
Number of subjects: 75
Study: 30316305

Group type: EXPERIMENTAL
Intervention: Motivational interviewing with the decision aid
Number of subjects: 0

Group type: COMPARATOR
Intervention: Motivational interviewing alone (control)
Number of subjects: 0
Study: 26694904

Group type: EXPERIMENTAL
Intervention: Low intensity shock wave treatment (12 sessions of 1,500 pulses of 0.09 mJ/mm(2) at 120 shock waves per minute)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Low intensity shock wave treatment
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Low intensity shock wave treatment after sham treatment
Number of subjects: 58

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 58
Study: 25223173

Group type: EXPERIMENTAL
Intervention: GnRHa 3.6 mg by subcutaneous injection starting from the 1st day to the 5th day of menstruation, once per 28 days (Observation 1 group)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: GnRHa 3.6 mg by subcutaneous injection in combination with Wenshen Xiaozheng Decoction (WXD) starting from the 1st day to the 5th day of menstruation, once per 28 days, plus WXD for 7 doses, one cycle per every 28 days (Observation 2 group)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Control group (no adjuvant therapy)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 134
Study: 22710267

Group type: EXPERIMENTAL
Intervention: Nitrous oxide
Number of subjects: 1773

Group type: COMPARATOR
Intervention: No nitrous oxide
Number of subjects: 1773
Study: 20578384

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 196

Group type: COMPARATOR
Intervention: Western medication (Tiapride tablets)
Number of subjects: 196
Study: 17672075

Group type: EXPERIMENTAL
Intervention: Warfarin therapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Warfarin and low-dose ASA
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: CYP2C9*3 variant
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: CYP2C9 genotype determination
Number of subjects: 60
Study: 14692964

Group type: EXPERIMENTAL
Intervention: Leukoreduced blood products
Number of subjects: 645

Group type: COMPARATOR
Intervention: Control group (non-leukoreduced blood products)
Number of subjects: 645

Group type: EXPERIMENTAL
Intervention: Study patients who did not receive transfusion
Number of subjects: 645

Group type: COMPARATOR
Intervention: Control patients who did not receive transfusion
Number of subjects: 645
Study: 11782647

Group type: EXPERIMENTAL
Intervention: CFS patients (male)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: CFS patients (female)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: CFS patients (both genders)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Controls (male)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Controls (female)
Number of subjects: 33
Study: 9825249

Group type: EXPERIMENTAL
Intervention: Flupenthixol decanoate maintenance therapy
Number of subjects: 62
Study: 7544932

Group type: EXPERIMENTAL
Intervention: Endoscopic laser ablation of the prostate (ELAP)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Transurethral resection of the prostate (TURP)
Number of subjects: 151
Study: 2553326

Group type: EXPERIMENTAL
Intervention: Intravenous nutrition (0.18 g of N + 125 kJ day‐1 kg‐1) for 3 or 7 days before laparotomy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Hospital diet only
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Intravenous nutrition
Number of subjects: 30
Study: 1054609

Group type: EXPERIMENTAL
Intervention: Dibromomannitol (DBM)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Busulfan
Number of subjects: 40
Study: 31538703

Group type: EXPERIMENTAL
Intervention: Partial breast irradiation (PBI)
Number of subjects: 66126

Group type: EXPERIMENTAL
Intervention: Hypofractionation (HF)
Number of subjects: 66126

Group type: EXPERIMENTAL
Intervention: Conventional whole breast RT (CWBI)
Number of subjects: 66126

Group type: EXPERIMENTAL
Intervention: No RT
Number of subjects: 66126

Group type: COMPARATOR
Intervention: Omission of RT
Number of subjects: 66126

Group type: EXPERIMENTAL
Intervention: HF
Number of subjects: 66126

Group type: COMPARATOR
Intervention: T1N0 subgroup analysis
Number of subjects: 66126
Study: 30415141

Group type: EXPERIMENTAL
Intervention: Information package (brochure, video, personalized phone call reminder) delivered through home visits by specially trained agents
Number of subjects: 2000

Group type: COMPARATOR
Intervention: Control group (no information package)
Number of subjects: 2000
Study: 28934714

Group type: EXPERIMENTAL
Intervention: DHEA 75mg/day
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 25962885

Group type: EXPERIMENTAL
Intervention: Intervention (multifaceted, interdisciplinary KT intervention)
Number of subjects: 5478

Group type: COMPARATOR
Intervention: Control (no additional intervention)
Number of subjects: 5478
Study: 23598900

Group type: EXPERIMENTAL
Intervention: Virtual walking training program using a real-world video recording for 30 mins a day, three times a week, for 6 weeks
Number of subjects: 14

Group type: COMPARATOR
Intervention: Treadmill gait training for 30 mins a day, three times a week, for 6 weeks
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Virtual walking training program using a real-world video recording
Number of subjects: 14

Group type: COMPARATOR
Intervention: Treadmill gait training
Number of subjects: 14
Study: 21527106

Group type: EXPERIMENTAL
Intervention: Medtronic NexSensor™ inserted in the abdomen
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Medtronic NexSensor™ inserted in the buttocks
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Medtronic NexSensor™ combined data from both sites
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Medtronic NexSensor™ at abdomen site
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Medtronic NexSensor™ at buttocks site
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Medtronic NexSensor™
Number of subjects: 63
Study: 19444280

Group type: EXPERIMENTAL
Intervention: High-dose ARB monotherapy (olmesartan medoxomil at 40 mg day(-1))
Number of subjects: 1200

Group type: COMPARATOR
Intervention: ARB plus CCB combination therapy (20 mg day(-1) olmesartan with amlodipine or azelnidipine)
Number of subjects: 1200
Study: 16762125

Group type: EXPERIMENTAL
Intervention: Hawthorn extract (1200 mg daily)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study: 15628632

Group type: EXPERIMENTAL
Intervention: Electrotherapy (high-frequency transcutaneous and intranasal electric stimulation of nasal muscles for 15 minutes, 3 times a week for 10 weeks)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 11688933

Group type: EXPERIMENTAL
Intervention: High-protein formula enriched with arginine, fiber, and antioxidants
Number of subjects: 220

Group type: COMPARATOR
Intervention: Standard high-protein formula
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: High-protein formula enriched with arginine, fiber, and antioxidants (for >2 days)
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: High-protein formula enriched with arginine, fiber, and antioxidants (for medical patients)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Standard high-protein formula (for medical patients)
Number of subjects: 220
Study: 9457607

Group type: EXPERIMENTAL
Intervention: Vancomycin (5 mg/kg, twice daily, 1 h infusions)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 72
Study: 7898905

Group type: EXPERIMENTAL
Intervention: Nonrigid internal fixation and 6 weeks of maxillomandibular fixation (Group 1)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Rigid internal fixation and immediate postoperative function (Group 2)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Rigid internal fixation with maxillomandibular fixation for a mean of 14 days (Group 3)
Number of subjects: 33
Study: 3074614

Group type: EXPERIMENTAL
Intervention: Flunarizine (10 mg before sleeping)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Betahistine dichlorhydrate (8 mg 3 times daily)
Number of subjects: 117
Study: 30561638

Group type: EXPERIMENTAL
Intervention: Higher BMI
Number of subjects: 0
Study: 28019091

Group type: EXPERIMENTAL
Intervention: Nivolumab (0.3-10.0 mg/kg)
Number of subjects: 1895

Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 1895
Study: 25852210

Group type: EXPERIMENTAL
Intervention: Composite score of acute-phase reactants (fibrinogen, C-reactive protein)
Number of subjects: 886

Group type: EXPERIMENTAL
Intervention: Composite score of thrombolytic factors (fibrinogen, active and total plasminogen activator inhibitor [PAI]-1)
Number of subjects: 886

Group type: EXPERIMENTAL
Intervention: Composite score of cytokines/adipokines (tumor necrosis factor receptor-1 and -2, active and total PAI-1, IL-6)
Number of subjects: 886

Group type: EXPERIMENTAL
Intervention: Endothelial dysfunction score
Number of subjects: 886
Study: 23984885

Group type: EXPERIMENTAL
Intervention: High sensitivity setting of the Actiwatch
Number of subjects: 10

Group type: COMPARATOR
Intervention: Low sensitivity setting of the Actiwatch
Number of subjects: 10
Study: 20660503

Group type: EXPERIMENTAL
Intervention: LLHA made of 0.9 mm SS wire
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: LLHA made of 1.25 mm SS wire
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (no LLHA)
Number of subjects: 44
Study: 19351624

Group type: COMPARATOR
Intervention: 3 mg/kg infliximab every 8 weeks (arm A)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: 5 mg/kg infliximab every 8 weeks (arm B)
Number of subjects: 141
Study: 16719029

Group type: EXPERIMENTAL
Intervention: Daily multinutrient energy‐dense oral supplement (6.3 kJ/mL) for six weeks
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Tri‐weekly resistance training for 12 weeks
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Combined treatment (nutrition and resistance training)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Attention control plus usual care and general nutrition and exercise advice
Number of subjects: 100
Study: 12709775

Group type: EXPERIMENTAL
Intervention: Modafinil (200 mg/day followed by 400 mg/day)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Modafinil with a 2-day washout period
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Modafinil using a taper-down/titrate-up protocol
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (methylphenidate)
Number of subjects: 40
Study: 11257323

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 51

Group type: COMPARATOR
Intervention: Glibenclamide
Number of subjects: 51
Study: 9356532

Group type: EXPERIMENTAL
Intervention: Digestible cornstarch
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Partially indigestible cornstarch
Number of subjects: 8
Study: 8361609

Group type: EXPERIMENTAL
Intervention: 20 mg quinapril (1 x 20 mg tablet per day)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 40 mg of nifedipine retard tablets (1 x 20 mg tablet twice daily)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Both groups (quinapril and nifedipine)
Number of subjects: 20
Study: 3740675

Group type: EXPERIMENTAL
Intervention: Melphalan
Number of subjects: 3363

Group type: COMPARATOR
Intervention: Cyclophosphamide
Number of subjects: 3363

Group type: EXPERIMENTAL
Intervention: Any alkylating agent
Number of subjects: 3363

Group type: EXPERIMENTAL
Intervention: Chemotherapy (general)
Number of subjects: 3363
Study: 29658750

Group type: EXPERIMENTAL
Intervention: High-arousal positive (HAP)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: High-arousal negative (HAN)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Low arousal (LA)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Overall emotional arousal conditions (HAP, HAN, LA)
Number of subjects: 100
Study: 27270480

Group type: EXPERIMENTAL
Intervention: NA mFOLFOX6 chemotherapy alone (CS group, n = 48)
Number of subjects: 102

Group type: COMPARATOR
Intervention: NA mFOLFOX6 chemotherapy with radiation (RCS group, n = 54)
Number of subjects: 102
Study: 25402562

Group type: EXPERIMENTAL
Intervention: Intensive health education and behavioural intervention
Number of subjects: 474

Group type: COMPARATOR
Intervention: Conventional education
Number of subjects: 474
Study: 23018169

Group type: EXPERIMENTAL
Intervention: Self-care education program (group discussion, lectures, pamphlets)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 105
Study: 20565846

Group type: EXPERIMENTAL
Intervention: 16 week tailored exercise programme run by qualified exercise professionals at community sports centres
Number of subjects: 2104

Group type: COMPARATOR
Intervention: Information booklet on physical activity
Number of subjects: 2104
Study: 18298358

Group type: EXPERIMENTAL
Intervention: Circuit class therapy
Number of subjects: 68

Group type: COMPARATOR
Intervention: Individual therapy
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: No active shoulder control
Number of subjects: 68

Group type: COMPARATOR
Intervention: Active shoulder control
Number of subjects: 68
Study: 15688181

Group type: EXPERIMENTAL
Intervention: 0.75% Ropivacain
Number of subjects: 100

Group type: COMPARATOR
Intervention: 1% Mepivacain
Number of subjects: 100
Study: 12895689

Group type: EXPERIMENTAL
Intervention: Ginkgo biloba (120 mg/day, n=15)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo (n=16)
Number of subjects: 31
Study: 12486467

Group type: EXPERIMENTAL
Intervention: Extensile corset (n = 72)
Number of subjects: 143

Group type: COMPARATOR
Intervention: Traditional corset (n = 71)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Extensile corset (n = 30) without central obesity
Number of subjects: 143